John R. Walsh, M.D., F.A.C.P.; Robert E. Mass, M.D.; Frederic W. Smith, M.D.; Verna E. Lange, B.S.
This content is PDF only. Please click on the PDF icon to access.
Desferrioxamine (DF), an iron chelating substance, was given parenterally to four patients with idiopathic hemochromatosis, eight patients with cirrhosis of the liver associated with various degrees of iron stores, two patients with hemosiderosis related to blood transfusions, and two control patients. Control patients excreted insignificant amounts of iron in their urine (< 2.0 mg/24 hr), compared with patients with hemochromatosis and hemosiderosis (2.5 to 45 mg/24 hr). Clinical and pathological differentiation of idiopathic hemochromatosis from the hemosiderosis seen with Laennec's cirrhosis was difficult; some patients with the latter exhibited urinary iron excretion patterns similar to patients with hemochromatosis. Therefore, urinary
Learn more about subscription options.
Register Now for a free account.
Walsh JR, Mass RE, Smith FW, Lange VE. Iron Chelation with Desferrioxamine.. Ann Intern Med. 1964;60:728. doi: 10.7326/0003-4819-60-4-728_1
Download citation file:
Published: Ann Intern Med. 1964;60(4):728.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only